2026-05-19T01:29:20Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/237702024-11-28T16:02:24Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16938col_20.500.12105_16967

00925njm 22002777a 4500 dc Mas-Lladó, Caterina author Rosselló, Xavier author González-Del-Hoyo, Maribel author Pocock, Stuart author de Werf, Frans Van author Chin, Chee Tang author Danchin, Nicolas author Lee, Stephen W-L author Medina, Jesús author Huo, Yong author Bueno, Héctor author Mas-Lladó, Caterina author Rosselló, Xavier author González-Del-Hoyo, Maribel author Pocock, Stuart author de Werf, Frans Van author Chin, Chee Tang author Danchin, Nicolas author Lee, Stephen W-L author Medina, Jesús author Huo, Yong author Bueno, Héctor author 2023-10-12 Objective: We aimed to evaluate the applicability of the eligibility criteria of randomized controlled trials (RCTs) cited in guideline recommendations in a real-world cohort of patients receiving secondary prevention after acute myocardial infarction from the EPICOR registries. Methods: Recommendations provided by American and European guidelines for acute myocardial infarction were classified into general (applying to all patients) and specific (applying to patients with left ventricular dysfunction or heart failure). Randomized controlled trials cited in these recommendations were selected, and their entry criteria were applied to our international cohort of 18,117 patients. Results: There were 91.5% patients eligible for beta blockers (84.6% for general, and 5.9% for specific recommendations), 97.7% eligible for renin-angiotensin system inhibitor (angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers [ACEI/ARB]) recommendations (69.9% for general, 27.9% for specific) and 4.1% eligible for mineralocorticoid receptor antagonists (only specific recommendations). The percentages of patients with eligibility criteria who were discharged with a prescription of the recommended therapies were 80%-85% for beta blockers, 70%-75% for ACEI/ARB, and 29% for mineralocorticoid receptor antagonists. There were large regional variations in the percentage of eligible patients and in those receiving the medications (eg, 95% in Northern Europe and 57% in Southeast Asia for beta blockers). Conclusion: Most real-world acute myocardial infarction patients are eligible for secondary prevention therapy in both general and specific guideline recommendations, and the percentage of those on beta blockers and ACEI/ARB at hospital discharge is high. There are large regional variations in the proportion of patients receiving recommended therapies. Local targeted interventions are needed for quality improvement. Mas-Llado C, Rossello X, González-Del-Hoyo M, Pocock S, de Werf F Van, Chin CT, et al. Secondary prevention therapies in real-world patients with myocardial infarction: eligibility based on randomized trials supporting European and American guidelines. Am J Med. 2023 Oct. 10.1016/j.amjmed.2023.09.021 1555-7162 The American journal of medicine https://hdl.handle.net/20.500.13003/19944 37838236 L642504579 https://hdl.handle.net/20.500.12105/23770 Secondary prevention therapies in real-world patients with myocardial infarction: eligibility based on randomized trials supporting European and American guidelines